All patients
Age < 65y (younger) Age > 65y Age > 75y (older) BRAF mutant BRAF wild type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) previous systemic treatment (%) previous systemic treatment NO (%) Prior anti-CTLA4 benefit NO Prior anti-CTLA4 benefit YES stage III (locally advanced) stage IIIa stage IIIb stage IIIc stage IV (metastatic) stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/adv melanoma (mML), immune chekpoint inhibitors vs. pembrolizumab alone, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMspire-170, 2020 1.06 [0.69; 1.62]
KEYNOTE-006 (2 week), 2015 0.63 [0.47; 0.84]
KEYNOTE-006 (3 week), 2015 0.69 [0.52; 0.91]
0.74 [0.57 ; 0.97 ] IMspire-170, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 52% 1,558 moderate not evaluable deaths (OS) (extension)detailed results KEYNOTE-006 (2 week), 2015 0.68 [0.53; 0.87]
KEYNOTE-006 (3 week), 2015 0.68 [0.53; 0.87]
0.68 [0.57 ; 0.81 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,112 moderate not evaluable PFS (extension)detailed results KEYNOTE-006 (2 week), 2015 0.61 [0.50; 0.75]
KEYNOTE-006 (3 week), 2015 0.61 [0.50; 0.75]
0.61 [0.53 ; 0.70 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,112 moderate not evaluable progression or deaths (PFS)detailed results IMspire-170, 2020 1.15 [0.88; 1.50]
KEYNOTE-006 (2 week), 2015 0.58 [0.46; 0.73]
KEYNOTE-006 (3 week), 2015 0.58 [0.47; 0.72]
0.72 [0.48 ; 1.10 ] IMspire-170, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 89% 1,558 moderate not evaluable DCRdetailed results IMspire-170, 2020 0.91 [0.63; 1.32]
0.91 [0.63 ; 1.32 ] IMspire-170, 2020 1 0% 446 NA not evaluable objective responses (ORR)detailed results IMspire-170, 2020 0.77 [0.50; 1.17]
KEYNOTE-006 (2 week), 2015 3.77 [2.43; 5.86]
KEYNOTE-006 (3 week), 2015 3.63 [2.34; 5.65]
2.19 [0.77 ; 6.20 ] IMspire-170, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 94% 1,558 moderate not evaluable AE (any grade)detailed results IMspire-170, 2020 14.27 [3.34; 61.03]
14.27 [3.34 ; 61.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable AE (grade 3-4)detailed results IMspire-170, 2020 4.03 [2.70; 6.00]
4.03 [2.70 ; 6.00 ] IMspire-170, 2020 1 0% 436 NA not evaluable AE leading to death (grade 5)detailed results IMspire-170, 2020 1.39 [0.43; 4.44]
1.39 [0.43 ; 4.44 ] IMspire-170, 2020 1 0% 436 NA not evaluable STRAE (any grade)detailed results KEYNOTE-006 (2 week), 2015 0.67 [0.41; 1.09]
KEYNOTE-006 (3 week), 2015 0.63 [0.39; 1.03]
0.65 [0.46 ; 0.92 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable STRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable TRAE (any grade)detailed results KEYNOTE-006 (2 week), 2015 1.62 [1.07; 2.46]
KEYNOTE-006 (3 week), 2015 1.16 [0.78; 1.72]
1.36 [0.98 ; 1.90 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 25% 1,067 moderate not evaluable TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.84 [0.54; 1.30]
KEYNOTE-006 (3 week), 2015 0.82 [0.53; 1.28]
0.83 [0.61 ; 1.13 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.37 [0.11 ; 17.90 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-006 (2 week), 2015 0.74 [0.39; 1.40]
KEYNOTE-006 (3 week), 2015 1.23 [0.69; 2.18]
0.97 [0.60 ; 1.60 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 25% 1,067 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 1.85 [0.17; 20.50]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.16 [0.16 ; 8.29 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.04; 5.09]
KEYNOTE-006 (3 week), 2015 0.23 [0.01; 5.12]
0.35 [0.05 ; 2.37 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Chills TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.19 [0.06; 0.58]
KEYNOTE-006 (3 week), 2015 0.34 [0.14; 0.83]
0.27 [0.14 ; 0.54 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-006 (3 week), 2015 1.85 [0.06; 55.43]
1.85 [0.06 ; 55.43 ] KEYNOTE-006 (3 week), 2015 1 0% 533 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.32; 2.66]
KEYNOTE-006 (3 week), 2015 0.39 [0.10; 1.52]
0.66 [0.29 ; 1.54 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.70 [0.08 ; 6.00 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.30 [0.03; 2.95]
KEYNOTE-006 (3 week), 2015 0.92 [0.18; 4.62]
0.64 [0.17 ; 2.37 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 2.78 [0.29; 26.92]
KEYNOTE-006 (3 week), 2015 4.69 [0.54; 40.40]
3.66 [0.77 ; 17.46 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.35 [0.05 ; 2.37 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.37 [0.11 ; 17.90 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.35 [0.05 ; 2.37 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
0.35 [0.05 ; 2.37 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.70 [0.08 ; 6.00 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.06; 14.80]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.70 [0.08 ; 6.00 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
0.70 [0.08 ; 6.00 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.37 [0.11 ; 17.90 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.14; 7.03]
0.98 [0.14 ; 7.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable Anaemia AE (grade 3-4)detailed results IMspire-170, 2020 1.74 [0.50; 6.04]
1.74 [0.50 ; 6.04 ] IMspire-170, 2020 1 0% 436 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Asthenia AE (grade 3-4)detailed results IMspire-170, 2020 1.74 [0.50; 6.04]
1.74 [0.50 ; 6.04 ] IMspire-170, 2020 1 0% 436 NA not evaluable Constipation AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMspire-170, 2020 1.97 [0.07; 58.97]
1.97 [0.07 ; 58.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable Dermatitis acneiform AE (grade 3-4)detailed results Out of scale IMspire-170, 2020 22.68 [1.32; 388.47]
22.68 [1.32 ; 388.47 ] IMspire-170, 2020 1 0% 436 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMspire-170, 2020 4.44 [1.47; 13.42]
4.44 [1.47 ; 13.42 ] IMspire-170, 2020 1 0% 436 NA not evaluable Fatigue AE (grade 3-4)detailed results IMspire-170, 2020 1.65 [0.39; 7.00]
1.65 [0.39 ; 7.00 ] IMspire-170, 2020 1 0% 436 NA not evaluable Headache AE (grade 3-4)detailed results IMspire-170, 2020 1.97 [0.07; 58.97]
1.97 [0.07 ; 58.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable Hypertension AE (grade 3-4)detailed results IMspire-170, 2020 1.77 [0.73; 4.30]
1.77 [0.73 ; 4.30 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increase AST AE (grade 3-4)detailed results IMspire-170, 2020 3.00 [0.60; 15.03]
3.00 [0.60 ; 15.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMspire-170, 2020 1.99 [0.49; 8.06]
1.99 [0.49 ; 8.06 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increased Lipase Level AE (grade 3-4)detailed results IMspire-170, 2020 2.00 [0.59; 6.74]
2.00 [0.59 ; 6.74 ] IMspire-170, 2020 1 0% 436 NA not evaluable Nausea AE (grade 3-4)detailed results IMspire-170, 2020 10.02 [0.54; 184.60]
10.02 [0.54 ; 184.60 ] IMspire-170, 2020 1 0% 436 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.06; 15.80]
0.98 [0.06 ; 15.80 ] IMspire-170, 2020 1 0% 436 NA not evaluable Pruritus AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMspire-170, 2020 6.03 [0.72; 50.50]
6.03 [0.72 ; 50.50 ] IMspire-170, 2020 1 0% 436 NA not evaluable Rash AE (grade 3-4)detailed results IMspire-170, 2020 7.83 [1.77; 34.66]
7.83 [1.77 ; 34.66 ] IMspire-170, 2020 1 0% 436 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results IMspire-170, 2020 7.98 [0.42; 151.89]
7.98 [0.42 ; 151.89 ] IMspire-170, 2020 1 0% 436 NA not evaluable Sepsis AE (grade 3-4)detailed results IMspire-170, 2020 12.08 [0.67; 217.70]
12.08 [0.67 ; 217.70 ] IMspire-170, 2020 1 0% 436 NA not evaluable Vomiting AE (grade 3-4)detailed results IMspire-170, 2020 2.49 [0.48; 12.97]
2.49 [0.48 ; 12.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-03 08:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 283,284,70,235,285,68,127,128,286,69,129
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743